Skip to Content Facebook Feature Image

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

Business

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS
Business

Business

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

2026-01-20 18:14 Last Updated At:18:35

Global Trade Observatory Annual Outlook: 94% expect 2026 growth to match or exceed 2025 despite tariffs, costs and policy uncertainty

DAVOS, Switzerland, Jan. 20, 2026 /PRNewswire/ -- The global trade outlook looks fragile. Business confidence does not. That's the core finding of DP World's new Global Trade Observatory (GTO) Annual Outlook Report 2026, showing 94% of respondents expect 2026 trade growth to match or exceed the pace of 2025, despite rising frictions and volatility.

The findings are based on a survey of 3,500 senior supply chain and logistics executives across eight industries and 19 countries, conducted ahead of the World Economic Forum Annual Meeting in Davos.

In total, 54% expect trade growth to be faster than 2025 and 40% expect it to be equal. This is despite 53% anticipating high or very high policy uncertainty, 90% expecting trade barriers to rise or remain unchanged. Only 25% expect a negative impact on their business, with 49% expecting no effect and 26% even seeing a positive impact.

This frontline sentiment contrasts with some macro projections, with the IMF forecasting trade growth (by volume) could slow to 2.3% in 2026, down from an estimated 3.6% in 2025.

Asked where trade growth potential is greatest in 2026, executives most frequently pointed to Europe (22%) and China (17%), followed by Asia Pacific (14%) and North America (13%).

Sultan Ahmed bin Sulayem, Group Chairman and CEO of DP World, said: "Global trade is becoming increasingly complex, not less so. Our role is clear: to keep trade moving by understanding where friction exists, anticipating where it may emerge next, and investing in the infrastructure, capabilities and partnerships that help our customers operate more efficiently and reliably."

The GTO Annual Outlook was developed with Geneva-based insights agency, Horizon Group. Margareta Drzeniek, Managing Partner, Horizon Group, said: "What we're seeing is confidence with contingency plans. Executives are embedding resilience into strategy by diversifying suppliers, reassessing routes and adding options, because volatility is now the baseline. Those best positioned will be the ones who can turn those resilience plans into measurable performance."

What companies are doing differently in 2026

The survey indicates companies are responding to volatility by actively redesigning supply chains and trade routes. This includes:

  • Resilience as strategy: Supplier diversification (51%), higher inventories (44%), and friend-shoring (36%) are cited among the most common strategic shifts planned for 2026.
  • Route agility increases: 26% intend to use new routes, while 23% are evaluating them. Decisions are driven by cost savings (38%), improved connectivity/inland infrastructure (36%), and faster customs procedures/clearance times (35%).
  • Border friction remains a choke point: 60% cite customs clearance as a leading cause of delays and disruption. Executives also prioritise investment in warehousing and logistics hubs (39%), road networks (36%), and border/customs processing infrastructure (36%).

The DP World Global Trade Observatory (GTO) is a data- and insights-led platform designed to provide decision-makers with actionable intelligence on the forces reshaping global trade, grounded in research including a proprietary survey of 3,500 supply chain and logistics executives across eight industries and 19 countries. Research was conducted in November 2025 with Geneva-based insights agency Horizon Group.

For media enquiries, please contact:

Adal Mirza
Group Vice President
Adal.mirza@dpworld.com
+971 50 628 7856  

Hakam Kherallah
Group Senior Manager
Hakam.Kherallah@dpworld.com
+971 50 552 2610

Follow DP World on:
X (Twitter): https://twitter.com/DP_World
LinkedIn: https://www.linkedin.com/company/dp-world

About DP World

DP World is reshaping the future of global trade to improve lives everywhere. Operating across six continents with a team of over 125,000 employees, we combine global infrastructure and local expertise to deliver seamless supply chain solutions. From Ports and Terminals to Marine Services, Logistics and Technology, we leverage innovation to create better ways to trade, minimizing disruptions from the factory floor to the customer's door.

WE MAKE TRADE FLOW

 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

DP WORLD SURVEY: TRADE LEADERS UPBEAT ON 2026 DESPITE RISING BARRIERS

SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the "Research Without Borders • Tracing the Source with GENEIII" Global Evidence-Based Journey.

GENEIII joined forces with core partners to visit the National University of Singapore (NUS) and the Temasek Life Sciences Laboratory. The event facilitated a deep international dialogue centering on the transformation of ergothioneine from basic research to industrial application, and showcased the complete scientific value chain GENEIII has constructed with NUS and Temasek. This collaboration is achieving a dual track of "Global Layout of Frontier Research" and "Official National Certification for a Leading Brand," demonstrating the new heights in synthetic biology to the global market.

Furthermore, the company showcased its breakthroughs in pharmaceutical-grade manufacturing and registered human clinical research, establishing a new international standard for ergothioneine as a functional bioactive ingredient.

GENEIII is currently the sole internationally leading manufacturer of ergothioneine raw materials, achieving excellence in quality, production capacity, and cost efficiency. Through advanced synthetic biology and precision fermentation, GENEIII produces ergothioneine with 99.99% purity, exceptional molecular stability, and is odorless, overcoming long-standing challenges associated with this compound.

Production is carried out using 30-tonne industrial fermenters in accordance with cGMP pharmaceutical standards, ensuring consistent quality, full traceability, and reliable large-scale supply. This industrial capability fundamentally reshapes the global ergothioneine supply chain, enabling downstream applications in nutrition, health, and medical research to be built on a stable, pharmaceutical-grade foundation.

Beyond manufacturing leadership, GENEIII has taken a decisive step in advancing ergothioneine from laboratory research to human clinical validation. The company has conducted a series of human clinical trials officially registered with the Chinese Clinical Trial Registry and publicly disclosed on the National Health Commission of China's official platform.

These studies were carried out across tertiary hospitals, ensuring independent oversight, standardized clinical protocols, and high scientific credibility.
(Chinese Clinical Trial Registration Number: ChiCTR2400093739)

This clinical program represents the first systematically registered, hospital-based human validation of ergothioneine in the industry, setting a new benchmark for transparency and evidence-based development. By directly linking high-purity raw materials with measurable human outcomes, GENEIII has established a strong scientific foundation for the safe and effective application of ergothioneine.

GENEIII's integrated model—combining pharmaceutical-grade purity, industrial-scale manufacturing, and registered human clinical research—positions the company at the forefront of global ergothioneine innovation. As the industry moves toward higher regulatory standards and evidence-driven products, GENEIII continues to define what clinically validated, world-class ergothioneine truly means.

About GeneIII

At GeneIII, we are a biotechnology company at our core. Our patented bioengineering process redefines L-Ergothioneine production, delivering 99.99% purity, full transparency, and clinically backed results that set a new industry benchmark.

We are the first in the industry to achieve human clinical verification. Our work is supported by an expert advisory panel of eight leading professionals, led by the world-renowned anti-aging authority, Professor Barry Halliwell. Learn more at geneiii.com.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

Recommended Articles